"Pulmonary Arterial Hypertension Treatment Market - Insights into the Global Market Trends and Future Prospects"

Pulmonary Arterial Hypertension (PAH) is a chronic and progressive condition characterized by high blood pressure in the pulmonary arteries that supply blood to the lungs. The treatment market for PAH consists of various drugs, such as prostacyclins, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and soluble guanylate cyclase stimulators. In addition, some patients may require lung transplantation. The PAH treatment market is growing due to increasing awareness of the condition and the availability of new drugs and treatments. However, high costs associated with these drugs and limited access to advanced medical facilities in some regions may limit the growth of the market.

Increase in prevalence of lung cancer and lung-related disorders, rise in adoption of technologically advanced medical devices, and surge in the geriatric population have boosted the growth of the global pulmonary arterial hypertension market. The market across North America held the lion's share in 2021, accounting for more than two-fifths of the market.

Download Free Sample Report- https://www.alliedmarketresearch.com/request-sample/5470

Covid-19 scenario:

The Covid-19 outbreak positively affected the market due to rise in prevalence of Covid-19 infactions with patients already suffering from pulmonary artery hypertension.
However, the diagnosis and treatment of pulmonary hypertension and observation of elevated mortality risk in individuals severely affected during the pandemic.
The report segments the global pulmonary arterial hypertension market on the basis of drug type, type, route of administration, and region.

Based on drug type, the prostacyclin and prostacyclin analogs segment held the largest share in 2021, accounting for more than half of the market. In addition, the segment is estimated to register the highest CAGR of 5.5% during the forecast period.

On the basis of type, the branded segment dominated the market in terms of revenue in 2021, accounting for more than four-fifths of the market. However, the generics segment is estimated to register the highest CAGR of 5.7% from 2022 to 2031.

Based on route of administration, the oral segment held the largest share in 2021, accounting for nearly two-thirds of the market. In addition, the segment is projected to manifest the highest CAGR of 5.6% during the forecast period.

For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/5470

The global pulmonary arterial hypertension market is analyzed across several regions such as North America, LAMEA, Asia-Pacific, and Europe. The market across North America held the lion's share in 2021, accounting for more than two-fifths of the market. However, the market across Asia-Pacific is expected to register the highest CAGR of 7.2% from 2022 to 2031.

The global pulmonary arterial hypertension market report includes an in-depth analysis of the prime market players such as Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation and Viatris Inc.

The report analyzes these key players in the global pulmonary arterial hypertension market. These players have adopted various strategies such as new product launches, expansion, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments of every market player.

Other Trending Reports:

Lysosomal Disease Treatment Market: https://www.alliedmarketresearch.com/lysosomal-disease-treatment-market

Pharmaceutical Continuous Manufacturing Market: https://www.alliedmarketresearch.com/pharmaceutical-continuous-manufacturing-market

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.